about
Identification and characterization of a stage specific membrane protein involved in flagellar attachment in Trypanosoma bruceiEffects of epithelial to mesenchymal transition on T cell targeting of melanoma cellsWhole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanomaMismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Evolving role of tumor antigens for future melanoma therapies.The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.Tumor-specific T-cell help is associated with improved survival in melanoma.The good, the (not so) bad and the ugly of immune homeostasis in melanoma.Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC moleculesA First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaButyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
P50
Q27323987-C68DCFC2-28FE-4FD9-B452-07A20D19D40EQ34722210-7354457A-6B9C-42B8-8FED-81983AC33065Q35176032-09D1E4EF-71F3-47FD-84E8-0A74B7ED2C55Q36583731-3E0DFA41-23BB-4413-9607-37FB0152A941Q38221107-C3A0B9D0-E7FB-4B6F-9351-3A66B11EBC99Q38232855-DF34C322-49D9-4C64-848D-ABC7EBD91BDAQ41808041-20CA968B-DABB-4C09-819F-DEF4ACD8B9D1Q44315577-96B9269A-8A32-484F-A102-5F3AD8EF8E8CQ45217684-A622FC9B-91AB-47D8-9C0D-B63039F8DC25Q47988747-97A5B267-C0B8-48BB-8BD5-1AC33BF9DCDCQ48117613-1A308263-0634-4CA1-99D6-21164833241DQ52649833-192DEEA2-1F35-470B-87FE-83A9E7AEAE20Q54357319-89B6E719-27EE-4FA7-A9C2-032853AC7212Q54473462-F01C5C1C-6A9D-4165-A7E4-817D703FC201Q57805467-F586EFAB-1C4D-4A13-9D1C-11F4AF0A9559Q91632380-72F53ABE-6BEA-4511-A49B-9BCB02F5BDB3Q92525743-39A9DCBB-10B4-4077-A758-2B469AA6D113
P50
description
researcher, ORCID id # 0000-0003-3474-3104
@en
wetenschapper
@nl
name
Katherine Woods
@ast
Katherine Woods
@en
Katherine Woods
@es
Katherine Woods
@nl
type
label
Katherine Woods
@ast
Katherine Woods
@en
Katherine Woods
@es
Katherine Woods
@nl
prefLabel
Katherine Woods
@ast
Katherine Woods
@en
Katherine Woods
@es
Katherine Woods
@nl
P108
P106
P108
P1153
7101749507
P31
P496
0000-0003-3474-3104